The present invention provides a compound of formula I



I

or a pharmaceutically acceptable salt, hydrate, or prodrug thereof,

wherein each R^1 is independently

a) H,

b) C_{1-4} alkyl,

c) C_{1-4} alkyl substituted by a phenyl where the phenyl is optionally substituted with one or two R^2, or

d) phenyl, optionally substituted with one or two R^2;

R^2 is

a) halo,

b) OR^3,

c) CF_3

d) $C(=O)\text{-}NR^4R^5$,

e) $NH\text{-}SO_2\text{-}R^6$,

f) NR^4R^5,

g) $NR^4\text{-}C(=O)\text{-}R^4$,

h) $SO_2\text{-}NR^4R^5$,

i) CN, or

j) NO_2;

R^3 is H, C_{1-4} alkyl, or phenyl;

R^4 and R^5 are independently H, C_{1-4} alkyl, or R^4 and R^5 taken together with the attached nitrogen atom to form a ring selected from the group consisting of 1-pyrrolidinyl, 1-piperazinyl and 1-morpholinyl;

R^6 is H or C_{1-4} alkyl;

R^7 is

a) H, or

b) halo,

c) OR^3,

d) CF_3

e) $C(=O)-NR^4R^5$,

f) $NH-SO_2-R^6$,

g) NR^4R^5,

h) $NR^4-C(=O)-R^4$,

i) $SO_2-NR^4R^5$,

j) CN, or

k) NO_2;

R^8 is

a) H,

b) F,

c) Cl,

d) C_{1-4} alkyl,

e) C_{1-3} alkoxy,

f) CF_3,

g) C_{1-4} alkyl substituted by a phenyl wherein the phenyl is optionally substituted with one or two R^2,

h) phenyl, optionally substituted with one or two R^2,

i) OR^3,

j) $CO-NR^4R^5$,

k) NR^4R^5,

l) $NH-SO_2-R^6$, or

m) $NH-CO-R^4$;

at each occurrence, alkyl and alkoxy is optionally substituted with OH, halo, or NH_{2-i};

m is 1 to 2; and n is 1-3.